ARS Pharmaceuticals (SPRY) Capital Expenditures (QoQ) (2020 - 2025)
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) Capital Expenditures (QoQ) (2020 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.12 Mn | 417.27 Mn | 20.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 286.27% |
| Jun 30, 2025 | -43.96% |
| Mar 31, 2025 | -69.87% |
| Dec 31, 2024 | 115.71% |
| Sep 30, 2024 | 268.42% |
| Jun 30, 2024 | -54.22% |
| Mar 31, 2024 | 191.21% |
| Dec 31, 2023 | -311.63% |
| Sep 30, 2023 | 43.33% |
| Jun 30, 2023 | -84.46% |
| Mar 31, 2023 | 53.17% |
| Dec 31, 2022 | 320.00% |
| Sep 30, 2022 | 36.36% |
| Jun 30, 2022 | 4.76% |
| Mar 31, 2022 | 102.74% |
| Dec 31, 2021 | -981.61% |
| Sep 30, 2021 | -85.48% |
| Jun 30, 2021 | 340.44% |
| Mar 31, 2021 | -44.94% |
| Dec 31, 2020 | -60.92% |